Discontinued — last reported Q3 '19
Operating
Change in receivables
Year-over-year, this metric declined by 11146.7%, from -$15.00M to -$1.69B. Over 4 years (FY 2021 to FY 2025), Change in receivables shows a downward trend with a -26.1% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityVolatile
First reportedQ1 2013
Last reportedQ3 2019
How to read this metric
Significant fluctuations often reflect changes in supply chain financing arrangements or timing of payments from manufacturing partners.
Detailed definition
This broader metric includes changes in trade accounts receivable as well as other non-trade receivables, such as vendor...
Peer comparison
In complex global supply chains, this metric often fluctuates based on the timing of component purchasing and vendor rebates.
Metric ID:
change_in_receivablesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $693.00M | $260.00M | $168.00M | -$786.00M | $669.00M | $674.00M | $106.00M | $175.00M | $65.00M | $247.00M | $508.00M | -$479.00M | $1.02B | -$661.00M | -$143.00M | -$15.00M | $484.00M | -$155.00M | $0.00 | -$1.69B |
| QoQ Change | — | -62.5% | -35.4% | -567.9% | +185.1% | +0.7% | -84.3% | +65.1% | -62.9% | +280.0% | +105.7% | -194.3% | +312.7% | -164.9% | +78.4% | +89.5% | >999% | -132.0% | +100.0% | — |
| YoY Change | — | — | — | — | -3.5% | +159.2% | -36.9% | +122.3% | -90.3% | -63.4% | +379.2% | -373.7% | >999% | -367.6% | -128.1% | +96.9% | -52.5% | +76.6% | +100.0% | <-999% |
Range-$1.69B – $1.02B
CAGR+20.6%
Avg YoY Growth-616.3%
Median YoY Growth-20.2%
Change in receivables at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's change in receivables?
- Bristol-Myers Squibb (BMY) reported change in receivables of -$1.69B in Q1 2026.
- How has Bristol-Myers Squibb's change in receivables changed year-over-year?
- Bristol-Myers Squibb's change in receivables decreased by 11146.7% year-over-year, from -$15.00M to -$1.69B.
- What is the long-term trend for Bristol-Myers Squibb's change in receivables?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's change in receivables has grown at a -26.1% compound annual growth rate (CAGR), from $1.05B to $314.00M.
- What does change in receivables mean?
- The total change in all money owed to the company from both customers and other partners.